ABSTRACT
The U.S. Food and Drug Administration recently approved lonafarnib as the first treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies. This approval was primarily based on a comparison of patients with HGPS treated with lonafarnib in 2 open-label trials with an untreated patient cohort. With up to 11 years of follow-up, it was found that the lonafarnib treated patients with HGPS had a survival benefit of 2.5 years compared with the untreated patients with HGPS. This large treatment effect on the objective endpoint of mortality using a well-matched comparator group mitigated potential sources of bias and together with other evidence, established compelling evidence of a drug effect with benefits that outweighed the risks. This approval is an example of U.S. Food and Drug Administration's regulatory flexibility for a rare disease while ensuring that standards for drug approval are met.
Subject(s)
Progeria , United States , Humans , Progeria/drug therapy , Progeria/genetics , Lamin Type A/genetics , Piperidines/therapeutic use , Pyridines/therapeutic useABSTRACT
This publication describes uniform definitions for cardiovascular and stroke outcomes developed by the Standardized Data Collection for Cardiovascular Trials Initiative and the US Food and Drug Administration (FDA). The FDA established the Standardized Data Collection for Cardiovascular Trials Initiative in 2009 to simplify the design and conduct of clinical trials intended to support marketing applications. The writing committee recognizes that these definitions may be used in other types of clinical trials and clinical care processes where appropriate. Use of these definitions at the FDA has enhanced the ability to aggregate data within and across medical product development programs, conduct meta-analyses to evaluate cardiovascular safety, integrate data from multiple trials, and compare effectiveness of drugs and devices. Further study is needed to determine whether prospective data collection using these common definitions improves the design, conduct, and interpretability of the results of clinical trials.
Subject(s)
Cardiovascular Diseases/diagnosis , Data Collection/standards , Endpoint Determination/standards , Stroke/diagnosis , Clinical Trials as Topic , Humans , United States , United States Food and Drug AdministrationSubject(s)
17 alpha-Hydroxyprogesterone Caproate/therapeutic use , Drug Approval , Premature Birth/prevention & control , Progestins/therapeutic use , United States Food and Drug Administration , Advisory Committees , Black People , Clinical Trials as Topic , Europe , Female , Humans , Infant, Newborn , Pregnancy , Premature Birth/epidemiology , Premature Birth/ethnology , Product Recalls and Withdrawals , Risk Factors , Treatment Outcome , United States/epidemiologySubject(s)
Benzimidazoles/therapeutic use , Drug Approval , Serotonin Agents/therapeutic use , Sexual Dysfunctions, Psychological/drug therapy , United States Food and Drug Administration , Advisory Committees , Benzimidazoles/adverse effects , Drug Interactions , Female , Humans , Premenopause , Serotonin Agents/adverse effects , United StatesSubject(s)
Cardiovascular Diseases/chemically induced , Drug Labeling , Hypogonadism/drug therapy , Off-Label Use , Testosterone/therapeutic use , Advertising , Age Factors , Aged , Drug Industry , Drug Labeling/legislation & jurisprudence , Government Regulation , Humans , Male , Middle Aged , National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division , Testosterone/adverse effects , Testosterone/blood , United States , United States Food and Drug AdministrationSubject(s)
Antiemetics/therapeutic use , Dicyclomine/therapeutic use , Doxylamine/therapeutic use , Morning Sickness/drug therapy , Pyridoxine/therapeutic use , Congenital Abnormalities , Dicyclomine/adverse effects , Dicyclomine/history , Doxylamine/adverse effects , Doxylamine/history , Drug Approval/history , Drug Combinations , Female , History, 20th Century , Humans , Pregnancy , Pyridoxine/adverse effects , Pyridoxine/history , United States , United States Food and Drug AdministrationSubject(s)
Drug Approval , Hot Flashes/drug therapy , Paroxetine/therapeutic use , Selective Serotonin Reuptake Inhibitors/therapeutic use , Suicidal Ideation , Advisory Committees , Antineoplastic Agents, Hormonal/therapeutic use , Cytochrome P-450 CYP2D6/drug effects , Drug Interactions , Female , Humans , Paroxetine/pharmacology , Selective Serotonin Reuptake Inhibitors/pharmacology , Tamoxifen/therapeutic use , United States , United States Food and Drug AdministrationABSTRACT
PURPOSE: To describe a protocol for active surveillance of acute myocardial infarction (AMI) in users of a recently approved oral antidiabetic medication, saxagliptin, and to provide the rationale for decisions made in drafting the protocol. METHODS: A new-user cohort design is planned for evaluating data from at least four Mini-Sentinel data partners from 1 August 2009 (following US Food and Drug Administration's approval of saxagliptin) through mid-2013. New users of saxagliptin will be compared in separate analyses with new users of sitagliptin, pioglitazone, long-acting insulins, and second-generation sulfonylureas. Two approaches to controlling for confounding will be evaluated: matching by exposure propensity score and stratification by AMI risk score. The primary analyses will use Cox regression models specified in a way that does not require pooling of patient-level data from the data partners. The Cox models are fit to summarized data on risk sets composed of saxagliptin users and similar comparator users at the time of an AMI. Secondary analyses will use alternative methods including Poisson regression and will explore whether further adjustment for covariates available only at some data partners (e.g., blood pressure) modifies results. RESULTS: The results of this study are pending. CONCLUSIONS: The proposed protocol describes a design for surveillance to evaluate the safety of a newly marketed agent as postmarket experience accrues. It uses data from multiple partner organizations without requiring sharing of patient-level data and compares alternative approaches to controlling for confounding. It is hoped that this initial active surveillance project of the Mini-Sentinel will provide insights that inform future population-based surveillance of medical product safety.
Subject(s)
Adamantane/analogs & derivatives , Dipeptides/adverse effects , Hypoglycemic Agents/adverse effects , Myocardial Infarction/epidemiology , Adamantane/adverse effects , Cohort Studies , Confounding Factors, Epidemiologic , Dipeptidyl-Peptidase IV Inhibitors/adverse effects , Drug Approval , Follow-Up Studies , Humans , Myocardial Infarction/etiology , Poisson Distribution , Product Surveillance, Postmarketing/methods , Proportional Hazards Models , Regression Analysis , United States/epidemiology , United States Food and Drug AdministrationABSTRACT
Testosterone replacement therapy has been approved in the United States since the 1950s for men with "classical" hypogonadism. These men have specific and well-recognized hypothalamic, pituitary, or testicular conditions leading to deficient or absent endogenous testosterone. A more controversial treatment population is aging men, many with comorbidities, who have low serum testosterone concentrations compared with young healthy men and who do not have the well-recognized medical conditions that cause "classical" hypogonadism. Testosterone continues to be widely used in these men with "age-related hypogonadism" even though the benefits of testosterone for this use are uncertain and there are important risks, including a potential risk of major adverse cardiac events for the testosterone class, and two testosterone products with increases in blood pressure that can increase the risk of myocardial infarction and stroke. Given the uncertain clinical benefit of testosterone in men with "age-related hypogonadism" in the face of known and potential adverse outcomes, none of the testosterone products is FDA approved for such use.
ABSTRACT
All medications currently approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus are indicated to improve glycemic control. Since 1995, FDA has used HbA1c as the primary basis for approval of these therapies because a reduction in blood glucose lessens the symptoms of hyperglycemia and lowering of HbA1c has been shown to reduce the risk for some of the chronic complications of diabetes. Despite evidence of clinical benefit with therapies that reduce HbA1c, concerns have been raised that some diabetes medications may increase cardiovascular risk in a patient population that is already vulnerable to cardiovascular disease. Therefore, FDA convened a public advisory committee meeting to discuss the role of cardiovascular assessment in the pre-approval and post-approval settings for medications developed for the treatment of type 2 diabetes. After considering the advisory panel's recommendations and other data, FDA published a guidance document requesting evidence showing that new treatments for type 2 diabetes do not result in an unacceptable increase in cardiovascular risk. This review article begins by summarizing the events leading up to publication of this guidance. Subsequent sections discuss the guidance itself as well as general considerations for implementing the new cardiovascular recommendations. The new approach to developing medications for the treatment of type 2 diabetes will lead to evaluation in patients more representative of those who will use these therapies, if approved, and will help healthcare providers make informed decisions when choosing a medication within the growing treatment armamentarium for type 2 diabetes.
Subject(s)
Diabetes Mellitus/drug therapy , Drug Approval/methods , Hypoglycemic Agents/therapeutic use , Blood Glucose/metabolism , Cardiovascular Diseases/chemically induced , Cardiovascular Diseases/prevention & control , Clinical Trials as Topic/standards , Diabetes Mellitus, Type 2/drug therapy , False Negative Reactions , Glycated Hemoglobin/drug effects , Humans , Hyperglycemia/drug therapy , Insulin/therapeutic use , Research Design/standards , Risk , United States , United States Food and Drug AdministrationABSTRACT
This publication describes uniform definitions for cardiovascular and stroke outcomes developed by the Standardized Data Collection for Cardiovascular Trials Initiative and the U.S. Food and Drug Administration (FDA). The FDA established the Standardized Data Collection for Cardiovascular Trials Initiative in 2009 to simplify the design and conduct of clinical trials intended to support marketing applications. The writing committee recognizes that these definitions may be used in other types of clinical trials and clinical care processes where appropriate. Use of these definitions at the FDA has enhanced the ability to aggregate data within and across medical product development programs, conduct meta-analyses to evaluate cardiovascular safety, integrate data from multiple trials, and compare effectiveness of drugs and devices. Further study is needed to determine whether prospective data collection using these common definitions improves the design, conduct, and interpretability of the results of clinical trials.
Subject(s)
Cardiovascular Diseases/diagnosis , Clinical Trials as Topic , Endpoint Determination/trends , Stroke/diagnosis , Cardiac Catheterization/mortality , Cardiac Catheterization/trends , Cardiovascular Diseases/mortality , Cardiovascular Diseases/surgery , Clinical Trials as Topic/methods , Endpoint Determination/mortality , Heart Valve Prosthesis Implantation/mortality , Heart Valve Prosthesis Implantation/trends , Hospitalization/trends , Humans , Prospective Studies , Risk Assessment/trends , Stroke/mortality , Stroke/surgeryABSTRACT
CONTEXT: Impaired coronary circulatory function predicts cardiovascular events, the leading cause of death in patients with diabetes mellitus. Aldosterone causes cardiovascular injury and is not suppressed by chronic angiotensin converting enzyme (ACE) inhibitor therapy. OBJECTIVE: Our objective was to assess whether mineralocorticoid receptor activation contributes to coronary circulatory dysfunction in patients with diabetes who are already receiving ACE inhibitor therapy. DESIGN AND SETTING: A randomized, double-blind, crossover study with an intervening washout period of at least 4 wk was conducted with ambulatory patients from the community. PATIENTS: Patients included 16 subjects (11 men, eight Caucasians; mean age, 53 yr; mean body mass index, 38.0 kg/m2) with diabetes and albuminuria but without clinical cardiovascular disease. INTERVENTIONS: ACE inhibitors were switched to enalapril 20 mg daily, and other antihypertensives were discontinued. Amlodipine 5-10 mg daily was added to achieve blood pressures less than 130/80 mm Hg. Subjects then received, in random order, 6 wk of the mineralocorticoid receptor antagonist eplerenone 50 mg (with placebo pill) daily and 6 wk of another diuretic, hydrochlorothiazide 12.5 mg (with potassium 10 mEq) daily. MAIN OUTCOME MEASURES: Before and after each 6-wk treatment period, we measured coronary circulatory function (adenosine-stimulated myocardial perfusion reserve) and endothelial function (brachial artery reactivity and peripheral arterial tonometry). RESULTS: The eplerenone and hydrochlorothiazide groups had similar blood pressures, serum potassium, glycemia, and endothelial function. Although pretreatment myocardial perfusion reserve did not differ between groups, myocardial perfusion reserve was significantly higher after eplerenone than after hydrochlorothiazide (median 1.57 vs. 1.30; P = 0.03). CONCLUSIONS: Mineralocorticoid receptor blockade improves coronary circulatory function compared with hydrochlorothiazide in patients with diabetes already receiving ACE inhibitor therapy.
Subject(s)
Coronary Circulation/drug effects , Diabetic Nephropathies/drug therapy , Diuretics/administration & dosage , Hydrochlorothiazide/administration & dosage , Mineralocorticoid Receptor Antagonists/administration & dosage , Spironolactone/analogs & derivatives , Adult , Albuminuria/drug therapy , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Blood Glucose , Blood Pressure/drug effects , Brachial Artery/physiology , Cross-Over Studies , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Drug Therapy, Combination , Eplerenone , Female , Humans , Male , Middle Aged , Pilot Projects , Potassium/blood , Renal Circulation , Spironolactone/administration & dosageABSTRACT
One of the critical path initiatives of the Food and Drug Administration (FDA) is to accelerate the development and availability of a safe and effective artificial pancreas for the treatment of diabetes mellitus. The FDA has established a multidisciplinary group of scientists and clinicians, in partnership with the National Institutes of Health (NIH), to address the clinical, scientific and regulatory challenges related to this unique medical product.:
ABSTRACT
PURPOSE: C-reactive protein (CRP), androgens, and menopausal loss of endogenous estrogens are associated with cardiovascular disease (CVD). We hypothesized that high androgens, low estradiol, and low sex hormone-binding globulin (SHBG) would be associated with high CRP in postmenopausal women. METHODS: CRP, SHBG, estradiol, and total testosterone were measured using baseline bloods of 221 hormone therapy (HT)-nonusers and 162 HT-users from a cross-sectional analysis in a nested case-control sample of the Women's Health Study. Hormones and CRP were ln-transformed and relationships were assessed with Spearman correlations and linear regression. RESULTS: ln-SHBG (beta=-0.40; p<0.01) and ln-testosterone (beta=-0.24; p=0.04) were the only independent hormonal predictors of ln-CRP among HT-nonusers after adjusting for age, hypertension, smoking, body mass index, diabetes, exercise, HDL cholesterol, alcohol intake, and CVD occurrence during follow-up. Upon stratification, the association between ln-SHBG and ln-CRP persisted among HT nonusers who subsequently developed CVD (beta=-0.55; p=0.01), but not among women who remained CVD-free (p=0.28). The inverse relationship between ln-SHBG and ln-CRP was strongest among the leanest women. None of the sex-hormones predicted ln-CRP among HT-users. CONCLUSIONS: SHBG and total testosterone were inversely associated with CRP among HT nonusers in this study. The relationship between SHBG and CRP was more strongly inverse among leaner women.
Subject(s)
C-Reactive Protein/analysis , Cardiovascular Diseases/blood , Postmenopause/blood , Sex Hormone-Binding Globulin/analysis , Testosterone/blood , Aged , Biomarkers , Cardiovascular Diseases/prevention & control , Case-Control Studies , Cross-Sectional Studies , Double-Blind Method , Estradiol/blood , Estrogen Replacement Therapy , Female , Humans , Linear Models , Middle Aged , Predictive Value of Tests , Risk FactorsABSTRACT
BACKGROUND: Upper-extremity deep vein thrombosis (UEDVT) occurs spontaneously or sometimes develops as a complication of pacemaker use, long-term use of a central venous catheter (CVC), or cancer. METHODS AND RESULTS: To improve our understanding of UEDVT, we compared the demographics, symptoms, risk factors, prophylaxis, and initial management of 324 (6%) patients with central venous catheter (CVC)-associated UEDVT, 268 (5%) patients with non-CVC-associated UEDVT, and 4796 (89%) patients with lower-extremity DVT from a prospective US multicenter DVT registry. The non-CVC-associated UEDVT patients were younger (59.2+/-18.2 versus 64.2+/-16.9 years old; P<0.0001), less often white (65% versus 73%; P<0.01), leaner (body mass index [BMI] 26.8+/-7.1 versus 28.5+/-7.3 kg/m2; P<0.001), and more likely to smoke (19% versus 13%; P=0.02) than the lower-extremity DVT patients. By way of propensity analysis and multivariable logistic regression analysis, we determined that an indwelling CVC was the strongest independent predictor of UEDVT (odds ratio [OR], 7.3; 95% confidence interval [CI], 5.8 to 9.2). An age of <67 years, a BMI of <25 kg/m2, and hospitalization were the independent predictors of non-CVC-associated UEDVT. Most (68%) UEDVT patients were evaluated while they were inpatients. Only 20% of the 378 UEDVT patients who did not have an obvious contraindication to anticoagulation received prophylaxis at the time of diagnosis. CONCLUSIONS: UEDVT risk factors differ from the conventional risk factors for lower-extremity DVT. Our findings identify deficiencies in our current understanding and the prophylaxis of UEDVT and generate hypotheses for future research efforts.
Subject(s)
Arm/blood supply , Registries , Thrombophlebitis/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Anticoagulants/therapeutic use , Case Management , Catheterization, Central Venous/adverse effects , Cross-Sectional Studies , Female , Humans , Immobilization/adverse effects , Inpatients , Leg/blood supply , Male , Middle Aged , Neoplasms/complications , Neoplasms/epidemiology , Obesity/epidemiology , Organ Specificity , Postoperative Complications/epidemiology , Prospective Studies , Pulmonary Embolism/epidemiology , Racial Groups , Risk Factors , Smoking/epidemiology , Thinness/epidemiology , Thrombolytic Therapy , Thrombophlebitis/diagnostic imaging , Thrombophlebitis/etiology , Ultrasonography , United StatesSubject(s)
Cardiovascular Diseases/chemically induced , Diabetes Mellitus, Type 2/drug therapy , Drug Approval , Hypoglycemic Agents/adverse effects , Thiazolidinediones/adverse effects , Advisory Committees , Glycated Hemoglobin , Humans , Rosiglitazone , United States , United States Food and Drug AdministrationABSTRACT
Factors that predispose to thrombus propagation from the femoropopliteal veins to the pelvic veins are poorly understood. Our goal was to determine whether there are characteristics that identify patients with massive deep vein thrombosis (DVT). We compared the 122 (2.5%) patients presenting with massive DVT (pelvic plus lower-extremity DVT) to the 4,674 (97.5%) patients with isolated lower-extremity DVT from a prospective United States multicenter DVT registry. Patients with massive DVT were younger (59.4+/-18.9 years vs. 64.3+/-16.8 years; p<0.01), less likely to have hypertension (40% vs. 51%; p=0.02), and more likely to smoke (21% vs. 13%; p=0.02) and have ongoing radiation therapy (7% vs. 3%; p=0.02). The massive DVT group more commonly presented with extremity edema (80% vs. 69%; p<0.01) and erythema (21% vs. 12%; p<0.01) than the isolated lower-extremity DVT group. However, after multivariable logistic regression analysis, extremity erythema (adjusted odds ratio 1.86; 95% CI 1.13-3.04) was the only independent sequela of massive DVT and younger age (adjusted odds ratio 1.17 per decreasing decade of age; 95% confidence interval: 1.02-1.34) was the only independent predictor of massive DVT. Thrombus propagation from the femoropopliteal system cannot be reliably predicted using demographic or clinical characteristics.
Subject(s)
Venous Thrombosis/diagnostic imaging , Venous Thrombosis/epidemiology , Adult , Aged , Anticoagulants/therapeutic use , Comorbidity , Female , Heparin, Low-Molecular-Weight/therapeutic use , Humans , Male , Middle Aged , Predictive Value of Tests , Prospective Studies , Registries , Risk Factors , Ultrasonography , Venous Thrombosis/drug therapy , Venous Thrombosis/prevention & control , Warfarin/therapeutic useABSTRACT
Two cytochrome P450 2C9 (CYP2C9) polymorphisms, CYP2C9*2 and *3, metabolize warfarin inefficiently. We assessed the extent to which these polymorphisms explain very low warfarin dose requirements and hemorrhagic complications after excluding non-genetic determinants of warfarin dosing. In this retrospective observational study, 73 patients with stable warfarin doses for > or =1 month and International Normalized Ratios (INR) of 2.0-3.0 were enrolled from our Anticoagulation Clinic. Seventeen patients required < or =2 mg (low-dose), 41 required 4-6 mg (moderate-dose), and 15 required > or =10 mg (high-dose) of daily warfarin. CYP2C9 genotyping was assessed by PCR amplification and restriction enzyme digestion analysis of DNA isolated from circulating leukocytes. The CYP2C9 polymorphisms independently predicted low warfarin requirements after adjusting for Body Mass Index, age, acetaminophen use, and race (OR 24.80; 95% CI 3.83-160.78). At least one polymorphism was present in every patient requiring < or =1.5 mg of daily warfarin, and 88%, 37%, and 7% of the low-, moderate-, and high-dose groups, respectively. All homozygotes and compound-heterozygotes for the variant alleles were in the low-dose group. Rates of excessive (INR>6.0) anticoagulation (and bleeding) were 4.5 (6.0), 7.9 (7.9), and 14.7 (0) per 100 patient-years in the wild-types, heterozygotes, and compound heterozygotes/homozygotes, respectively. In conclusion, CYP2C9*2 or *3 compound heterozygotes and homozygotes have low warfarin requirements even after excluding liver disease, excessive alcohol or acetaminophen consumption, low body weight, advancing age, and drug interactions. These polymorphisms increase the rate of excessive anticoagulation, but this risk does not appear to be associated with higher bleeding rates when anticoagulation status is closely monitored.